About
UltraDAO.

UltraDAO is a groundbreaking biotechnology consortium at the forefront of Ultrasound Neuromodulation research and development. Our mission is to harness cutting-edge ultrasonic stimulation techniques, data-driven insights, and advanced AI models to pioneer a new class of "digi-ceuticals"—digitally generated medicines with the capacity to redefine traditional pharmaceutical paradigms.

By converging innovative hardware, software, and treatment protocols, we aim to usher in a new era of patient-centric, precision-guided therapies that are safer, more accessible, and more adaptable than conventional drug-based approaches.

From our early milestones in securing intellectual property through NFT-based licensing platforms, to the upcoming launch of our user-flashable Ultrasound Mod1 4th Edition Device, we are relentlessly advancing the science and practice of neuromodulation. Our technology pipeline and research timelines are carefully designed to demonstrate clear value creation at every stage—starting with Alzheimer's and dementia voice-based analytical tools, followed by novel frequency "Loading Blocks" that dynamically alter on-device parameters, ultimately culminating in clinical trials that validate our approach against current gold-standard treatments.

In parallel, we are building a vibrant, value-driven ecosystem around two tokens, both bought with KAS (Kaspa), the network's money: $ULTRA, the spending token used to access and deploy next-generation digi-ceutical treatments on the device; and UXDT, voting stock in the UltraDAO LLC — an ownership share that also steers what we research. By leveraging the Kaspa ($KAS) network, a world-class blockchain infrastructure, we ensure that our tokenized economy remains secure, transparent, and efficient. Through open markets and community participation, our shareholders play a direct role in shaping the evolution of our technologies, therapies, and broader patient-support framework.

Above all, we at UltraDAO are committed to ethical innovation, rigorously validated research, and meaningful collaborations. We believe that our ultrasound-based digi-ceutical therapies will fundamentally transform how patients and practitioners think about treatment—pushing beyond traditional drugs to deliver personalized, dynamic, and continuously evolving solutions that truly meet the needs of a changing world.